VITA 34 AG Vita 34 AG / Key word(s): Investment
01.07.2015 15:17
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Vita 34 AG acquired 30 percent of company shares of the cooperation partner Bio Save (Serbia)
Leipzig, July 1, 2015 - Vita 34 AG (WKN: A0BL84) has acquired 30 percent of company shares of the cooperation partner Bio Save d.o.o. (Serbia). The purchase is fully financed out of liquid funds from Vita 34.
Bio Save will be fully integrated into the Vita 34 Group with this transaction. Thereby Vita 34 will improve its benefits from the regional presence of Bio Save in the Eastern European Market. The revenue of Bio Save Group in fiscal year 2014 accounted to EUR 1.7 million with an operating result of around EUR 0.3 million.
Vita 34 is storing cord blood units since April 2012 for Bio Save customers from Serbia, Montenegro, Macedonia, Bosnia and Herzegovina, Croatia und Slovenia. The laboratory processing and storage of the umbilical cord blood and tissue in accordance with the high standards set by German pharmaceutical law is, therefore, ensured.
Additional information:
ISIN: DE000A0BL849
WKN: A0BL84
Ticker symbol: V3V
Market segment: Regulated Market (Prime Standard) of the Frankfurt Stock Exchange
Vita 34 AG
Deutscher Platz 5
04103 Leipzig
Germany
END OF THE AD-HOC NOTICE
01.07.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: ir@vita34.de
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart
End of Announcement DGAP News-Service
|
distributed by
|
